Maxigen Biotech (TPE:1783) Beta: -0.3527 (As of Jun. 26, 2026)


TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$38.10
GF Value NT$60.99
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Beta?

Maxigen Biotech TPE:1783 -1.55% 87 Beta is -0.3527 as of Jun. 26, 2026. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$60.99 (Significantly Undervalued).

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Maxigen Biotech's Beta is -0.3527.


Maxigen Biotech  (TPE:1783) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Maxigen Biotech Beta Related Terms


Maxigen Biotech Beta Historical Data

* Premium members only.

The historical data trend for Maxigen Biotech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maxigen Biotech Beta Chart

Maxigen Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.66 1.33 0.51 0.63 0.00

Maxigen Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.00 0.00 0.00 0.00

TPE:1783 vs ISRG, BDX, MDLN: Beta Comparison

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Beta distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Beta falls into.


TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maxigen Biotech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.3527 mean?
Maxigen Biotech (TPE:1783) has a Beta of -0.3527 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Maxigen Biotech and its competitors.
Is Maxigen Biotech's Beta too high?
Maxigen Biotech's current Beta is -0.3527. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Beta compare to ISRG and BDX?
Maxigen Biotech's Beta of -0.3527 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Maxigen Biotech and its competitors. Maxigen Biotech's current Beta is -0.3527. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$60.99, compared to a current price of NT$38.10 — trading 37.5% below its estimated fair value. The current Beta is -0.3527. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Beta is -0.3527 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$38.10 is trading 37.5% below its estimated GF Value™ of NT$60.99. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Beta: -0.3527
  • GF Value™: NT$60.99 vs. price of NT$38.10 (37.5% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.10
Price
NT$60.99
GF Value